Overview

Neuramis® Volume Lidocaine for Volume Augmentation in the Mid-Face

Status:
Completed
Trial end date:
2020-03-09
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the effectiveness and safety of Neuramis® Volume Lidocaine for volume augmentation in the mid-face.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Medy-Tox
Treatments:
Lidocaine
Criteria
Inclusion Criteria:

1. Male or female 20 to 75 years of age

2. Subjects who desire volume augmentation to correct deficit in the mid-face volume that
is rated as Grade 3, 4, or 5 on the Facial Volume Scale

Exclusion Criteria:

1. Subjects who have received anti coagulation, anti-platelet, or thrombolytic
medications, anti-inflammatory drugs.

2. Subjects who have undergone facial plastic surgery in the face area below the level of
the lower orbital rim, tissue grafting, or tissue augmentation with silicone, fat, or
other permanent, or semi-permanent dermal fillers or are planning to undergo any of
these procedures at any time during the clinical investigation.